LifeSci Capital Boosts Price Target on Olema Pharmaceuticals, Citing Promising Breast Cancer Drug Pipeline
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.